1. Home
  2. SKYA vs XLO Comparison

SKYA vs XLO Comparison

Compare SKYA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKYA

SkyAI Inc. Common Stock

N/A

Current Price

$1.24

Market Cap

52.9M

Sector

Health Care

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$9.44

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYA
XLO
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.9M
49.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
SKYA
XLO
Price
$1.24
$9.44
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
350.9K
34.5K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.91
$0.46
52 Week High
$1.23
$9.89

Technical Indicators

Market Signals
Indicator
SKYA
XLO
Relative Strength Index (RSI) 67.82 64.20
Support Level $0.91 $0.62
Resistance Level N/A N/A
Average True Range (ATR) 0.10 0.56
MACD 0.02 0.06
Stochastic Oscillator 93.07 75.36

Price Performance

Historical Comparison
SKYA
XLO

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: